-
2023-507933-12-00
5
2022-08-18
Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
-
2023-509345-12-00
5
2022-06-22
Multiple Sclerosis
-
2023-504737-41-00
5
2022-06-10
Moderately to Severely Active Crohn's Disease
-
2024-515226-81-00
5
2022-06-02
Myocardial Injury after Noncardiac Surgery
-
2023-507795-51-00
5
2022-05-17
atherosclerotic heart and blood vessel disease (the narrowing of arter
-
2024-517083-32-00
4
2021-12-17
Myasthenia gravis
-
2023-506926-35-00
5
2021-09-24
Atherosclerotic cardiovascular disease, chronic kidney disease and sys
-
2023-504447-14-00
10
2021-07-29
Treatment of pediatric subjects with moderate to severe chronic plaque
-
2024-517253-27-00
5
2021-07-01
Acute lymphoblastic leukemia
-
2023-504454-35-00
5
2021-06-22
Neoplasms, Breast
-
2023-504997-39-00
5
2021-06-14
Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2
-
2024-514502-31-00
5
2021-01-11
Prurigo Nodularis
-
2023-506515-18-00
5
2020-10-23
Primary Progressive Multiple Sclerosis (PPMS)
-
2023-506467-34-00
5
2020-10-20
Relapsing Multiple Sclerosis (MS)
-
2024-514404-13-00
5
2020-10-01
Atopic Dermatitis
-
2022-502841-91-00
5
2020-08-12
Crohn’s Disease
-
2024-515669-32-00
5
2020-06-30
Pulmonary arterial hypertension
-
2024-515156-21-00
5
2020-01-09
Ulcerative Colitis
-
2023-506551-23-00
5
2019-11-21
Recurrent or primary advanced (Stage III or IV) endometrial cancer
-
2023-504718-31-00
10
2019-10-19
Moderately to Severely Active Ulcerative Colitis
-
2023-505980-36-00
5
2019-09-19
Primary progressive multiple sclerosis (PPMS)
-
2023-509059-15-00
7
2019-04-30
Malignant solid tumors: endometrial carcinoma (EC), urothelial carcino
-
2024-510605-28-00
5
2018-11-27
Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer
-
2024-516662-11-00
5
2018-11-23
Ovarian epithelial
cancer